HC Wainwright assumed coverage on shares of Perspective Therapeutics (NYSE:CATX – Get Free Report) in a research report issued to clients and investors on Thursday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $10.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 275.94% from the company’s current price.
Other analysts have also issued research reports about the company. Oppenheimer reduced their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. Wedbush reiterated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Friday, January 24th. Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $24.00 to $5.00 in a report on Monday, November 25th. Royal Bank of Canada reiterated an “outperform” rating and set a $16.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, January 14th. Finally, Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Monday. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $14.56.
Check Out Our Latest Stock Analysis on Perspective Therapeutics
Perspective Therapeutics Stock Performance
Hedge Funds Weigh In On Perspective Therapeutics
Several hedge funds have recently bought and sold shares of the business. FMR LLC increased its position in Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after buying an additional 5,370,392 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Perspective Therapeutics by 8.0% in the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after purchasing an additional 355,685 shares during the last quarter. Deerfield Management Company L.P. Series C grew its position in shares of Perspective Therapeutics by 4.3% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock valued at $9,375,000 after purchasing an additional 120,991 shares during the last quarter. Octagon Capital Advisors LP grew its position in shares of Perspective Therapeutics by 62.1% in the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock valued at $7,352,000 after purchasing an additional 882,528 shares during the last quarter. Finally, State Street Corp grew its position in shares of Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after purchasing an additional 1,192,812 shares during the last quarter. 54.66% of the stock is owned by institutional investors and hedge funds.
About Perspective Therapeutics
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Recommended Stories
- Five stocks we like better than Perspective Therapeutics
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Nu Holdings: Is Brazil’s Fintech Leader a Buy at This Discount?
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 Magnificent 7 Stocks Trading Near 50-Day Lows—Time to Buy?
- Best Stocks Under $10.00
- 3 Stocks With Ironclad Balance Sheets for Long-Term Stability
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.